Oral News and Research

RSS

Tengion 2010 adjusted net loss decreases to $25.8 million

Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.

25 Mar 2011

Merck to return rights for betrixaban to Portola

Portola Pharmaceuticals and Merck, known as MSD outside the United States and Canada, today announced that Merck plans to return to Portola all rights for betrixaban, an investigational oral Factor Xa inhibitor anticoagulant being evaluated for the prevention of stroke in patients with atrial fibrillation (SPAF). This decision was made following a review of Merck's investigational portfolio.

25 Mar 2011

Positive Phase 3 results from Tarsa's ORACAL study validates Unigene's oral peptide drug delivery technology

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the statistically significant top-line results released by its licensee, Tarsa Therapeutics, validate its proprietary oral peptide drug delivery technology.

25 Mar 2011

Study finds that 25% of health messages in school text books lack scientific evidence

Most school text books contain messages about health, but 24.6% of these are not based on any scientific evidence, according to a study by the Knowledge Management Unit at Baza Hospital (Granada), published in the journal BMC Public Health.

25 Mar 2011

Dabigatran etexilate is less costly, more effective for stroke treatment in patients with AF

A new economic analysis, published online in Thrombosis and Haemostasis, suggested that Boehringer Ingelheim's novel oral direct thrombin inhibitor dabigatran etexilate is cost-effective compared to current treatment options, particularly in real-world clinical practice.

25 Mar 2011

USPTO issues Notice of Allowance to AlphaRx ARX8203 pain product candidate

AlphaRx Inc. has received a Notice of Allowance from the United States Patent and Trademark Office for its lead pain product candidate code named ARX8203, a potentially safer drug intended for pain treatment.

25 Mar 2011

Positive results from Tarsa's oral calcitonin Phase III trial against postmenopausal osteoporosis

Tarsa Therapeutics today announced that the Phase III ORACAL trial of its oral recombinant salmon calcitonin in the treatment of postmenopausal osteoporosis was successfully concluded and yielded statistically significant, positive top-line results.

25 Mar 2011

Experts to present latest advances in bone research at annual European meeting

Today, the European Congress on Osteoporosis and Osteoarthritis opened in Valencia, Spain with some 4000 international participants. The Congress is the major annual European meeting in the bone field and attracts clinicians, specialists and bone experts from around the world. ECCEO11-IOF continues until March 26th at Valencia's Palacio de Congresos.

24 Mar 2011

SGIM honors BUSM professor with Clinician Investigator Award for quality of care research

Adam Rose, MD, MSc, an assistant professor of medicine at Boston University School of Medicine, has accepted the Society of General Internal Medicine's New England Region 2011 Clinician Investigator Award for his contributions to quality of care research.

24 Mar 2011

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Amgen today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia® (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis.

24 Mar 2011

Oral contraceptive use before pregnancy does not pose respiratory problems in children

A new study by researchers at RTI International, the National Institute of Environmental Health Sciences, and the Norwegian Institute of Public Health refutes previous findings that oral contraceptive use before pregnancy is linked to respiratory problems in children.

24 Mar 2011

NephRx receives new U.S. patent for NX002 to treat IBD

NephRx Corporation today announced issuance of a new U.S. patent for use of its novel growth factor peptide NX002 as a potential treatment for inflammatory bowel disease.

24 Mar 2011

Gilead's elvitegravir Phase III trial against HIV-1 meets primary objective

Gilead Sciences, Inc. today announced that the Phase III clinical trial of its investigational antiretroviral agent elvitegravir, a novel oral integrase inhibitor being evaluated for the treatment of HIV-1 infection in treatment-experienced patients, met its primary objective.

24 Mar 2011

Oramed reports successful completion of ORMD-0801 oral insulin toxicity study

Oramed Pharmaceuticals Inc., a developer of oral delivery systems, announced today that it has successfully completed a comprehensive toxicity study for its flagship oral insulin capsule, ORMD-0801.

24 Mar 2011

NephRx receives new U.S. patent for NX002 to treat oral mucositis

NephRx Corporation today announced issuance of a new U.S. patent for its novel peptide NX002, which currently is in preclinical development for the treatment of oral mucositis.

23 Mar 2011

MnSOD oral drug can protect against lung cancer radiation therapy

Patients with advanced non-small cell lung cancer can safely take an experimental oral drug intended to protect healthy tissue from the effects of radiation, according to a study led by researchers at the University of Pittsburgh Cancer Institute and published in this month's issue of Human Gene Therapy.

23 Mar 2011

MD Anderson receives $2.7 million NCI grant for acupuncture study in cancer

The University of Texas MD Anderson Cancer Center has been awarded a grant to study whether xerostomia, a debilitating side effect caused by head and neck cancer radiation treatment, can be prevented when acupuncture is part of a patient's treatment regimen.

23 Mar 2011

Dabigatran etexilate cost-effective compared to current care for stroke prevention in AF patients

A new health economic analysis, published today online in Thrombosis and Haemostasis, suggested that Boehringer Ingelheim's novel oral direct thrombin inhibitor, dabigatran etexilate, is cost-effective compared to current treatment options, particularly in "real-world" clinical practice.

23 Mar 2011

Opinions: Counterfeit medicines; oral rehydration therapy in Bangladesh; increasing access to safe drinking water; attracting R&D for health issues in Latin America

"The Obama administration and Congress should continue efforts to strengthen the safety of America's drug supply and, simultaneously, coordinate a global response to the problem of counterfeit drugs," Thomas Kubic, president & CEO of the Pharmaceutical Security Institute and a former deputy assistant director at the FBI, writes in a post on The Hill's "Congress Blog," where he describes the health risks associated with such drugs.

23 Mar 2011

Astellas announces positive results from mirabegron phase III trials against OAB

Astellas Pharma Inc. today announced the results of two pivotal phase III clinical trials for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder, show mirabegron significantly improves key OAB symptoms - urinary incontinence and frequency of micturition.

23 Mar 2011

Oral News and Research

Tengion 2010 adjusted net loss decreases to $25.8 million

Merck to return rights for betrixaban to Portola

Positive Phase 3 results from Tarsa's ORACAL study validates Unigene's oral peptide drug delivery technology

Study finds that 25% of health messages in school text books lack scientific evidence

Dabigatran etexilate is less costly, more effective for stroke treatment in patients with AF

USPTO issues Notice of Allowance to AlphaRx ARX8203 pain product candidate

Positive results from Tarsa's oral calcitonin Phase III trial against postmenopausal osteoporosis

Experts to present latest advances in bone research at annual European meeting

SGIM honors BUSM professor with Clinician Investigator Award for quality of care research

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Oral contraceptive use before pregnancy does not pose respiratory problems in children

NephRx receives new U.S. patent for NX002 to treat IBD

Gilead's elvitegravir Phase III trial against HIV-1 meets primary objective

Oramed reports successful completion of ORMD-0801 oral insulin toxicity study

NephRx receives new U.S. patent for NX002 to treat oral mucositis

MnSOD oral drug can protect against lung cancer radiation therapy

MD Anderson receives $2.7 million NCI grant for acupuncture study in cancer

Dabigatran etexilate cost-effective compared to current care for stroke prevention in AF patients

Opinions: Counterfeit medicines; oral rehydration therapy in Bangladesh; increasing access to safe drinking water; attracting R&D for health issues in Latin America

Astellas announces positive results from mirabegron phase III trials against OAB

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News